Stockscreener 앱 받기
283.90
1.33%
3.73
전일 마감가:
$280.17
열려 있는:
$280.75
하루 거래량:
827.36K
Relative Volume:
0.90
시가총액:
$41.63B
수익:
$5.15B
순이익/손실:
$1.40B
주가수익비율:
29.85
EPS:
9.51
순현금흐름:
$1.65B
1주 성능:
+1.68%
1개월 성능:
+10.64%
6개월 성능:
+19.82%
1년 성능:
+32.55%
1일 변동 폭
$279.61
$284.74
1주일 범위
$276.66
$293.08
52주 변동 폭
$199.92
$293.08
Resmed Inc Stock (RMD) Company Profile
명칭
Resmed Inc
전화
(858) 746-2400
주소
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
RMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
283.90 | 41.12B | 5.15B | 1.40B | 1.65B | 9.51 |
|
ISRG
Intuitive Surgical Inc
|
470.08 | 169.94B | 9.15B | 2.61B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
193.50 | 49.41B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.75 | 41.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
240.98 | 17.06B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | 개시 | Morgan Stanley | Overweight |
| 2025-01-16 | 개시 | Goldman | Buy |
| 2025-01-10 | 개시 | Piper Sandler | Neutral |
| 2024-12-13 | 개시 | Stifel | Hold |
| 2024-09-24 | 개시 | Robert W. Baird | Outperform |
| 2024-09-18 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-25 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-06-24 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-09-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | 업그레이드 | Needham | Hold → Buy |
| 2023-09-05 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-08-01 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 개시 | UBS | Buy |
| 2023-04-14 | 개시 | Mizuho | Buy |
| 2023-01-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-10-20 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-09-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-08-15 | 다운그레이드 | CLSA | Buy → Outperform |
| 2022-08-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-08-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-28 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-01-13 | 업그레이드 | CLSA | Outperform → Buy |
| 2022-01-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-10-22 | 업그레이드 | CLSA | Underperform → Outperform |
| 2021-08-02 | 다운그레이드 | CLSA | Outperform → Sell |
| 2021-08-02 | 다운그레이드 | Needham | Buy → Hold |
| 2021-07-28 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 개시 | RBC Capital Mkts | Underperform |
| 2021-06-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-06-22 | 업그레이드 | Macquarie | Neutral → Outperform |
| 2021-06-22 | 개시 | Robert W. Baird | Neutral |
| 2021-06-21 | 재확인 | Needham | Buy |
| 2021-06-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-09 | 업그레이드 | CLSA | Sell → Outperform |
| 2021-05-21 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-05-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-04-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Needham | Hold → Buy |
| 2020-11-02 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-30 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-10-27 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2020-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-05-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 개시 | CLSA | Underperform |
| 2020-01-31 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-01-10 | 개시 | Oppenheimer | Perform |
| 2019-11-22 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | 업그레이드 | UBS | Neutral → Buy |
| 2019-07-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-05-06 | 업그레이드 | UBS | Neutral → Buy |
| 2019-04-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-01-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2019-01-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2018-10-26 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 개시 | Goldman | Buy |
모두보기
Resmed Inc 주식(RMD)의 최신 뉴스
RESMED INC SEC 10-K Report - TradingView
ResMed Inc. Officer Plans Sale of Shares Under Rule 144 - TipRanks
ResMed Inc. Reports Change in Beneficial Ownership - TipRanks
ResMed CFO Adjusts Stock Holdings in Routine Transaction - TipRanks
ResMed Ranks 453rd in $260M Volume as Institutional Buys and Earnings Beat Fuel Analyst Price Hikes - AInvest
Macro Intelligence: ResMed breathes easy with FY2025 financial growth - ig.com
ResMed Stock Slides on 39.59% Volume Drop to $280M Ranks 425th as Analysts Hike Targets to $290-$325 Amid Strong Earnings and Dividend Boost - AInvest
ResMed is an ASX share market success story that deserves your attention - MSN
Resmed Inc Reports Increase in CHESS Depositary Interests - TipRanks
ResMed Inc Announces Proposed Sale of Common Shares - MSN
ResMed's Insider Sales and Institutional Confidence: Navigating Strategic Implications for Long-Term Investment - AInvest
Why Austal, Credit Corp, EOS, and ResMed shares are racing higher today - MSN
Stock Analysis | ResMed OutlookMixed Technicals, Strong Fundamentals, and Earnings in Focus - AInvest
ResMed earnings: Solid showing from ASX healthcare winner - Morningstar
ResMed Draws Analyst Skepticism After Apnimed Announces Positive Results From Investigational Sleep Apnea Drug: Retail’s Unmoved - MSN
What does Macquarie think Resmed shares are worth after its result? - The Motley Fool Australia
Research Alert: CFRA Maintains Buy Recommendation On Shares Of Resmed Inc. - 富途牛牛
ResMed share price is on watch for all-time highs - The Motley Fool Australia
ResMed Inc. stock rises Monday, outperforms market - MSN
Is ResMed Inc. a good long term investmentAchieve breakthrough financial results - Jammu Links News
What is ResMed Inc. company’s growth strategyGrow your portfolio with growth-oriented stocks - Jammu Links News
What does JP Morgan think Resmed shares are worth after reviewing its FY25 result? - MSN
Is ResMed Inc. a growth stock or a value stockConsistently profitable trades - Jammu Links News
What catalysts could drive ResMed Inc. stock higher in 2025Unlock exclusive trading strategies for gains - Jammu Links News
Does ResMed Inc. stock perform well during market downturnsInvest smarter with daily trading signals - Jammu Links News
What is the dividend policy of ResMed Inc. stockRapid wealth multiplication - Jammu Links News
How volatile is ResMed Inc. stock compared to the marketBuild wealth faster with expert stock selection - Jammu Links News
When is ResMed Inc. stock expected to show significant growthInvest smarter and grow your wealth faster - Jammu Links News
How strong is ResMed Inc. company’s balance sheetOutstanding capital returns - Jammu Links News
Should I hold or sell ResMed Inc. stock in 2025Market-leading capital gains - Jammu Links News
How does ResMed Inc. compare to its industry peersFind the best stocks for sustainable growth - Jammu Links News
What analysts say about ResMed Inc. stockGet daily updates on promising stocks - Jammu Links News
ResMed outlines 61%–63% gross margin target for FY26 while ramping up share buybacks and dividend - MSN
What are the technical indicators suggesting about ResMed Inc.Invest confidently with data-driven strategies - Jammu Links News
What makes ResMed Inc. stock price move sharplyBuild a winning investment strategy today - Jammu Links News
ResMed Receives Buy Rating from J.P. Morgan with A$48 Price Target - AInvest
ResMed's Q4 2025: Unpacking Contradictions in Gross Margin, Market Growth, and FX Impact - AInvest
US$290That's What Analysts Think ResMed Inc. (NYSE:RMD) Is Worth After These Results - Yahoo Finance
A Quick Look at Today's Ratings for ResMed(RMD.US), With a Forecast Between $290 to $325 - 富途牛牛
Why ResMed Inc. stock attracts strong analyst attentionMoney Making Low Risk Plans - beatles.ru
ResMed's Q4 Earnings Signal a Sleep Tech Titan's Unstoppable Momentum - AInvest
ResMed Earnings Call: Strong Growth and Strategic Vision - TipRanks
ResMed share price hits record high on strong FY25 results - MSN
Why Capstone Copper, Flight Centre, ResMed, and SKS shares are pushing higher today - MSN
ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings - Benzinga
ResMed Stock Rises After Strong Q4 Earnings Beat ExpectationsNews and Statistics - IndexBox
ResMed (RMD) Stock Is Up, What You Need To Know - Yahoo Finance
ResMed Earnings: Solid Gross Margin Expansion and US Mask Sales Drive Growth - Morningstar
ResMed (RMD) Price Target Increased by Piper Sandler to $270 - GuruFocus
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets - Morningstar
ResMed (RMD) Price Target Increased by Baird Analyst Amid Strong Fundamentals - GuruFocus
Resmed Inc (RMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.35%
자본화:
|
볼륨(24시간):